Free Trial
TSE:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
C$1.42
C$1.42
52-Week Range
N/A
Volume
339 shs
Average Volume
12,447 shs
Market Capitalization
C$16.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
REUN stock logo

About Reunion Neuroscience Stock (TSE:REUN)

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

REUN Stock News Headlines

EF Hutton Reaffirms Their Buy Rating on Reunion Neuroscience (REUN)
See More Headlines
Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Net Income
C$-38,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$4.86 million
Book Value
C$1.82 per share

Miscellaneous

Free Float
N/A
Market Cap
C$16.64 million
Optionable
Not Optionable
Beta
4.20
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Hannan Fleiman (Age 42)
    Co-Founder & Non-Independent Director
    Comp: $282.64k
  • Dr. Nathan Bryson B.Sc. (Age 59)
    Ph.D., Chief Science Officer
    Comp: $411.37k
  • Mr. Gregory T. Mayes Esq. (Age 54)
    J.D., Pres, CEO & Director
  • Mr. Edward F. Smith CPA (Age 52)
    Chief Financial Officer
  • Mr. Curtis Weber
    Gen. Counsel
  • Mr. Stephan Cote
    Head of Quality
  • Dr. Robert Alexander M.D.
    Chief Medical Officer & Sr. Advisor

REUN Stock Analysis - Frequently Asked Questions

How do I buy shares of Reunion Neuroscience?

Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

This page (TSE:REUN) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners